Article: How Cell and Gene Therapy Manufacturing Will Evolve in 2024
Summary: In this article, Catalent expert Rupa Pike to discusses the manufacturing requirements for a specific cell therapy gaining popularity: CAR T cell therapies.
Article: What Challenges Does the Advanced Therapies Sector Face?
Summary: In this article, Catalent commented on pricing and approval of advanced therapies.
Article: Scrip Asks…What Does 2024 Hold for Biopharma?
Summary: In this article, Catalent’s George Buchman was asked to respond and give insight into trends across cell and gene therapy and what we can expect to witness this year.
Article: Pharma Manufacturing: 2024 Pharma Predictions
Summary: In this article, Catalent expert, Victor Vinci was asked to respond and give his insight into manufacturing platforms and how they will help drugmakers meet demands.
Article: Getting Gene Therapy into the Fast Lane
Summary: In this article, Catalent expert George Buchman discusses the recent increase in gene therapy approvals & how we can accelerate the manufacturing speed with platform processes.
From Cell Collection to Commercial Contracting: Advancements in Cell & Gene Therapy Manufacturing (Part II)
In this episode of “The Top Line”, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing.